Tanvex BioPharma (KY) held an extraordinary shareholders' meeting yesterday (15th), approving the merger with Bora Biologics, a subsidiary of Bora Pharmaceuticals. This marks a significant step forward in Tanvex’s strategic alliance with Bora Pharmaceuticals, as the two companies work together to establish an international CDMO (Contract Development and Manufacturing Organization) team.

On August 27 this year, Tanvex and Bora Pharmaceuticals jointly announced their plan to merge with Bora Biologics, a company focused on large-molecule CDMO services. The terms of the merger include an exchange of one Tanvex BioPharma share for one Bora Biologics share. Upon completion of the transaction, Bora Pharmaceuticals will hold approximately 30.5% of Tanvex BioPharma’s shares, making it the largest single institutional shareholder of Tanvex.

Tanvex is Taiwan's first biotech company to receive FDA approval for the biosimilar drug Nypozi. In addition to its in-house development of biosimilars, Tanvex has also begun offering CDMO services for drug development and manufacturing. Tanvex has established a strong presence in the U.S., with an FDA-inspected cGMP facility in San Diego, which meets the manufacturing demands of the international market, particularly those based in the U.S. With the rapid growth of the biopharmaceutical market, Tanvex holds a strong competitive advantage. Combining forces with the Bora Group, which has demonstrated excellence in international CDMO services, will further enhance Tanvex's capabilities as a comprehensive biopharmaceutical company, giving it an even stronger competitive edge in the global market.

Resource (mandarin): 泰福通過合併保瑞生技案 拚共造國際CDMO戰隊